ArticleDiabetes2019
The Hypothalamic Arcuate Nucleus-Median Eminence Is a Target for Sustained Diabetes Remission Induced by Fibroblast Growth Factor 1.
Article in Diabetes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- Selective deletion of FGFR1 in AgRP neurons impairs energy homeostasis under high-fat diet in mice.Molecular metabolism · 2026Article
- High fat diet remodels the gene regulatory networks in the preoptic area.Scientific reports · 2026Article
- Overexpression of FGFR1 in AgRP neurons protects against obesity and improves glucose homeostasis.Frontiers in endocrinology · 2026Article
- Sustained diabetes remission induced by FGF1 involves a shift in transcriptionally distinct AgRP neuron subpopulations.Molecular metabolism · 2026Article
- A key role for parabrachial nucleus CGRP neurons in FGF1-Induced anorexia.Molecular metabolism · 2025Article
- AgRP neuron hyperactivity drives hyperglycemia in a mouse model of type 2 diabetes.The Journal of clinical investigation · 2025Article
- FGF-based drug discovery: advances and challenges.Nature reviews. Drug discovery · 2025Review
- Brain Defense of Glycemia in Health and Diabetes.Diabetes · 2024Review
- Review
- The Significance of Hypothalamic Inflammation and Gliosis for the Pathogenesis of Obesity in Humans.Endocrine reviews · 2023Review
- Autocrine FGF1 signaling promotes glucose uptake in adipocytes.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Sustained inhibition of NPY/AgRP neuronal activity by FGF1.JCI insight · 2022Article
- Glial cells as integrators of peripheral and central signals in the regulation of energy homeostasis.Nature metabolism · 2022Review
- Combined micro-osmotic pump infusion and intracerebroventricular injection to study FGF1 signaling pathways in the mouse brain.STAR protocols · 2022Article
- Metabolic Messengers: fibroblast growth factor 1.Nature metabolism · 2022Review
- The ventromedial hypothalamic nucleus: watchdog of whole-body glucose homeostasis.Cell & bioscience · 2022Review
- Central Nervous System Control of Glucose Homeostasis: A Therapeutic Target for Type 2 Diabetes?Annual review of pharmacology and toxicology · 2022Review
- Role of hypothalamic MAPK/ERK signaling and central action of FGF1 in diabetes remission.iScience · 2021Article
- Circulating α-klotho regulates metabolism via distinct central and peripheral mechanisms.Metabolism: clinical and experimental · 2021Review
- Central nervous system regulation of organismal energy and glucose homeostasis.Nature metabolism · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
In rodent models of type 2 diabetes (T2D), sustained remission of diabetic hyperglycemia can be induced by a single intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1). To identify the brain areas responsible for this effect, we first used immunohistochemistry to map the hypothalamic distribution of phosphorylated extracellular signal-related kinase 1/2 (pERK1/2), a marker of mitogen-activated protein kinase-ERK signal transduction downstream of FGF receptor activation. Twenty minutes after icv FGF1 injection in adult male Wistar rats, pERK1/2 staining was detected primarily in two hypothalamic areas: the arcuate nucleus-median eminence (ARC-ME) and the paraventricular nucleus (PVN). To determine whether an action of FGF1 localized to either the ARC-ME or the PVN is capable of mimicking the sustained antidiabetic effect elicited by icv FGF1, we microinjected either saline vehicle or a low dose of FGF1 (0.3 µg/side) bilaterally into either the ARC-ME area or PVN of Zucker Diabetic Fatty rats, a model of T2D, and monitored daily food intake, body weight, and blood glucose levels over a 3-week period. Whereas bilateral intra-arcuate microinjection of saline vehicle was without effect, remission of hyperglycemia lasting >3 weeks was observed following bilateral microinjection of FGF1 into the ARC-ME. This antidiabetic effect cannot be attributed to leakage of FGF1 into cerebrospinal fluid and subsequent action on other brain areas, since icv injection of the same total dose was without effect. Combined with our finding that bilateral microinjection of the same dose of FGF1 into the PVN was without effect on glycemia or other parameters, we conclude that the ARC-ME area (but not the PVN) is a target for sustained remission of diabetic hyperglycemia induced by FGF1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.